Eli Lilly and Boehringer Ingelheim have revealed positive results from a Phase III study of Jardiance in HFpEF patients
News
Gov’t sets out ten-year strategy for the UK’s life sciences sector
New ‘Life Sciences Vision’ outlines seven critical healthcare missions
Gov’t announces £2.45m funding to improve maternity safety
Almost £2m will be used for the first phase of the Avoiding Brain Injuries in Childbirth collaboration
BMA calls for some COVID-19 measures to remain after 19 July
Doctors’ union urges reconsideration of government plans to ditch mandatory wearing of facemasks
Oxford researchers launch HIV vaccine trial
Vaccine will be evaluated in 13 HIV-negative adults aged 18-65 years old
EC clears AstraZeneca’s acquisition of Alexion
Clearance in the UK is still pending and remains a requirement to complete the proposed deal
Spaces still available in the 2021 Marketer of the Year competition
Entries for the 2021 competition are well underway and PharmaTimes are calling on pharma marketers in a variety of roles to step forward and enter.
Merck KGaA and BioMed X launch new joint cancer research programme
New partnership will explore the role of extrachromosomal DNA in cancer
GSK and Alector ink neurodegenerative diseases partnership
Under the terms of the collaboration, Alector could receive up to $1.5bn in milestone payments
Over 600,000 COVID-19 tests genomically sequenced in the UK
The UK is estimated to contribute around 23% of all COVID-19 sequencing uploaded to GISAID
Queen awards the George Cross to the NHS for 73 years of service
The Queen has awarded the ‘unprecedented’ honour to staff for their response to the COVID-19 pandemic
Nonacus partners with Birmingham University to develop bladder cancer test
Nonacus is aiming to launch the ‘highly sensitive’ non-invasive bladder cancer test within 12 months
MHRA authorises Diurnal’s CAH therapy Efmody
Congenital adrenal hyperplasia (CAH) is a rare condition caused by deficiency of adrenal enzymes
Jazz Pharma’s blood cancer therapy Rylaze wins US approval
Rylaze has been specifically developed for patients who have developed hypersensitivity to E.coli-derived asparaginase
AZ says MPO inhibitor AZD4831 shows promise in heart failure study
AZD4831 is being investigated in patients with heart failure with preserved ejection fraction (HFpEF)
